CA
NZ
UK
AU
IND
US
…
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
PmV Pharmaceuticals Inc is a publicly listed biotechnology company; available public information about its pipeline and operations is limited. Its long-term growth may depend on advancing clinical programs, achieving regulatory approvals, securing partnerships and capital, and investors may find it attractive if milestones materially de‑risk prospects and enable commercial opportunities.
Material investment risks include clinical and regulatory failure, reliance on additional financing with potential dilution, limited disclosure and market liquidity, and high volatility from binary development outcomes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -79.91M | -74.81M | -68.96M | -73.33M | -57.82M |
| Net income | -77.74M | -58.71M | -68.96M | -73.32M | -57.85M |
| Selling general administrative | 16.33M | 26.92M | 24.25M | 25.05M | 21.80M |
| Selling and marketing expenses | - | - | 24.22M | - | - |
| Gross profit | -0.13M | -1.14M | -1.26M | - | - |
| Reconciled depreciation | 0.13M | 1.14M | 0.97M | 0.32M | 0.31M |
| Ebit | -79.91M | -74.81M | -68.96M | -77.36M | -58.60M |
| Ebitda | -79.78M | -73.67M | -67.70M | -77.04M | -58.29M |
| Depreciation and amortization | 0.13M | 1.14M | 1.26M | 0.32M | 0.31M |
| Non operating income net other | - | - | - | 3.71M | 0.47M |
| Operating income | -86.21M | -85.45M | -80.13M | -77.04M | -58.29M |
| Other operating expenses | 86.21M | 85.45M | 80.13M | 77.04M | 58.29M |
| Interest expense | - | - | - | 4.03M | 0.78M |
| Tax provision | -2.17M | -16.10M | 0.00M | -0.01M | 0.02M |
| Interest income | 6.34M | 10.65M | 9.80M | 3.63M | 0.45M |
| Net interest income | 6.34M | 10.65M | 9.80M | 3.63M | 0.45M |
| Income tax expense | -2.17M | -16.10M | 0.00M | -0.01M | 0.02M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 86.21M | 84.30M | 78.88M | 77.04M | 58.29M |
| Cost of revenue | 0.13M | 1.14M | 1.26M | - | - |
| Total other income expense net | 6.29M | 10.64M | 11.17M | 3.71M | 0.47M |
| Net income from continuing ops | -77.74M | -58.71M | -72.55M | -73.32M | -57.85M |
| Net income applicable to common shares | - | - | - | -73.32M | -57.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 116.56M | 191.29M | 252.15M | 270.31M | 331.57M |
| Other current assets | 2.28M | 6.20M | 3.53M | 5.13M | 3.30M |
| Total liab | 11.85M | 15.21M | 26.46M | 24.28M | 23.01M |
| Total stockholder equity | 104.71M | 176.08M | 225.69M | 246.03M | 308.56M |
| Other current liab | 7.86M | 7.44M | 9.94M | 7.31M | 8.63M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -446.45M | -368.71M | -310.00M | -241.04M | -167.73M |
| Other assets | - | - | 0.00M | 0.31M | 0.22M |
| Cash | 37.98M | 40.88M | 38.53M | 108.30M | 172.47M |
| Total current liabilities | 11.41M | 14.37M | 14.03M | 10.83M | 12.22M |
| Net debt | -37.15M | -39.69M | -25.24M | -94.32M | -161.27M |
| Short term debt | 0.40M | 0.35M | 0.85M | 0.53M | 0.40M |
| Short long term debt total | 0.84M | 1.19M | 13.29M | 13.98M | 11.19M |
| Other stockholder equity | 551.08M | 544.65M | 535.47M | 487.52M | 476.36M |
| Property plant equipment | - | - | - | 10.96M | 13.15M |
| Total current assets | 115.23M | 175.66M | 207.41M | 247.01M | 301.29M |
| Long term investments | 0.00M | 13.84M | 25.50M | 2.50M | 16.91M |
| Net tangible assets | - | - | - | 246.03M | 308.56M |
| Short term investments | 74.96M | 128.58M | 165.35M | 132.76M | 124.70M |
| Accounts payable | 3.15M | 6.58M | 3.24M | 3.00M | 3.19M |
| Accumulated other comprehensive income | 0.08M | 0.14M | 0.22M | -0.45M | -0.08M |
| Retained earnings total equity | - | - | - | -241.04M | -167.73M |
| Non currrent assets other | 0.30M | 0.23M | 0.19M | 0.31M | 0.22M |
| Non current assets total | 1.33M | 15.63M | 44.74M | 23.30M | 30.28M |
| Capital lease obligations | 0.84M | 1.19M | 13.29M | 13.98M | 11.19M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 70.17M | 53.35M | -24.73M | 6.62M | -142.24M |
| Change to liabilities | - | - | - | -1.71M | 0.19M |
| Total cashflows from investing activities | 70.17M | 53.35M | -50.55M | -1.37M | -143.58M |
| Total cash from financing activities | 0.51M | 0.31M | 35.58M | 0.96M | 2.02M |
| Change to operating activities | - | - | - | -0.18M | 3.93M |
| Net income | -77.74M | -58.71M | -68.96M | -73.32M | -57.85M |
| Change in cash | -2.89M | 2.35M | -70.59M | -64.17M | -188.13M |
| Begin period cash flow | 40.88M | 38.53M | 109.12M | 173.29M | 361.42M |
| End period cash flow | 37.98M | 40.88M | 38.53M | 109.12M | 173.29M |
| Total cash from operating activities | -73.58M | -51.28M | -55.66M | -63.76M | -46.57M |
| Issuance of capital stock | 0.00M | 0.00M | 35.12M | 0.00M | 0.00M |
| Depreciation | 0.13M | 1.14M | 1.26M | 0.32M | 0.31M |
| Other cashflows from investing activities | 0.03M | 0.25M | - | - | - |
| Sale purchase of stock | - | - | - | 0.96M | 2.02M |
| Other cashflows from financing activities | 0.51M | 0.31M | 0.46M | -1.37M | 2.02M |
| Change to netincome | - | - | - | 10.10M | 6.84M |
| Capital expenditures | 0.03M | 0.66M | 0.96M | 7.98M | 1.35M |
| Cash flows other operating | - | - | - | 1.48M | 1.01M |
| Cash and cash equivalents changes | - | - | - | -64.17M | -188.13M |
| Change in working capital | 0.91M | -1.59M | 5.43M | -0.57M | 4.12M |
| Stock based compensation | 5.92M | 8.87M | 12.38M | 10.20M | 5.34M |
| Other non cash items | -2.81M | -1.00M | -5.76M | -0.39M | 0.95M |
| Free cash flow | -73.61M | -51.94M | -56.62M | -71.74M | -47.92M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| PMVP Pmv Pharmaceuticals Inc |
0.04 3.28% |
1.26 | - | - | - | 1.09 | 1.24 |
| NVO Novo Nordisk A/S |
0.41 1.00% |
41.10 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
43.35 4.73% |
959.41 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
400 Alexander Park Drive, Princeton, NJ, United States, 08540
609 642 6670
54
| Name | Title | Year Born |
|---|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, CEO, Pres & Director | 1962 |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 1940 |
| Mr. Winston Kung M.B.A. | COO & CFO | 1976 |
| Dr. Deepika Jalota Pharm.D. | Chief Regulatory & Quality Assurance Officer | 1977 |
| Dr. Leila Alland M.D. | Chief Medical Officer | 1962 |
| Dr. Thomas E. Shenk Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1947 |
| Mr. Robert Ticktin | Gen. Counsel & Company Sec. | 1962 |
| Mr. Tim Smith | Sr. VP & Head of Corp. Devel. | NA |
| Dr. Binh Vu Ph.D. | Sr. VP of Drug Discovery & CMC | NA |
| Dr. David H. Mack Ph.D. | Co-Founder, CEO, President & Director | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.29%
Communication Services
+0.51%
Consumer Cyclical
-0.08%
Consumer Defensive
-0.14%
Energy
+1.08%
Financial Services
+0.14%
Financials
-0.06%
Healthcare
+0.51%
Industrials
+0.47%
Real Estate
-0.23%
Technology
+2.03%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...